PLANTATION, Fla., Feb. 28 /PRNewswire-FirstCall/ -- Viragen, Inc. (AMEX:VRA) today announced that the Company is scheduled to make a presentation at BioSquare 2006, a premier European biotechnology partnering conference, to be held in Geneva, Switzerland during March 8-10.
Presentation details are as follows: * Event: BioSquare 2006
Presenter: Charles A. Rice, President & CEO
When: Thursday, March 9, 2006 at 11:15 a.m. Where: Level 2, Room 7 Mr. Rice will discuss the Company's recent Swedish approval of Multiferon(R) (multi-subtype, natural human alpha interferon) for the first- line adjuvant treatment of high-risk (Stages IIb-III) malignant melanoma following dacarbazine (DTIC) after surgical removal of tumors.
"We have now launched our Multiferon(R) marketing program for melanoma in Sweden, and we expect sales to contribute to revenue growth in the coming months," stated Mr. Rice. "We will be working with regulatory authorities in the following weeks to implement our strategy for the European Union. In addition, plans are underway for our post-marketing clinical trial in melanoma with the next immediate steps being the selection of a Clinical Research Organization (CRO) and identification of investigational sites. We are also considering the inclusion of sites outside of the EU, in order to both support our international licensees and gain access to additional sources of patients." In addition, Mr. Rice will present on progress related to the OVA(TM) System and its humanized antibody programs targeting solid tumors.
In other news, the Company reported that it believes that a pending financing transaction will secure an immediate source of new working capital. Complete details are expected to be announced shortly.
About Viragen, Inc.: With global operations in the U.S., Scotland and Sweden, Viragen is a biotechnology company engaged in the research, development, manufacture and commercialization of pharmaceutical proteins for the treatment of viral diseases and cancers. Our product portfolio includes: Multiferon(R) (multi- subtype, natural human alpha interferon) targeting a broad range of infectious and malignant diseases; and humanized monoclonal antibodies targeting specific antigens over-expressed on many types of cancers. We are also pioneering the development of Avian Transgenic Technology, with the renowned Roslin Institute, as a revolutionary manufacturing platform for the large-scale, efficient and economical production of human therapeutic proteins and antibodies.
For more information, please visit: http://www.viragen.com/ Viragen, Inc. Corporate Contact:
Douglas Calder, Director of Communications
Phone: (954) 233-8746; Fax: (954) 233-1414
E-mail: The foregoing press announcement contains forward-looking statements that can be identified by such terminology such as "expects," "potential," "suggests," "may," "should," "could," or similar expressions. Such forward- looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management's expectations regarding future research, development and/or commercial results could be affected by, among other things, uncertainties relating to clinical trials and product development; availability of future financing; unexpected regulatory delays or government regulation generally; the Company's ability to obtain or maintain patent and other proprietary intellectual property protection; and competition in general. Forward-looking statements speak only as to the date they are made. The Company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made. First Call Analyst: FCMN Contact: dcalder@viragen.com http://www.newscom.com/cgi-bin/prnh/20010426/HSTH018LOGO-b http://www.newscom.com/cgi-bin/prnh/20060221/FLTU004 http://photoarchive.ap.org/ DATASOURCE: Viragen, Inc.
CONTACT: Douglas Calder, Director of Communications, Viragen, Inc., +1-954-233-8746, or fax, +1-954-233-1414, or Web site: http://www.viragen.com/
|